Abstract: The present invention relates to compositions and methods directed at screening or characterizing compounds that modulate the activity of calcium channels in cells preferably, calcium-release activated channels in cells. The compositions and methods can be used to produce inhibitors or activators of said channel, which represent leads or candidate therapeutic drugs for treating various pathological conditions. More specifically, the method comprises (a) contacting a test compound and a calcium channel activator, preferably an Icrac activator with a population of calcium channel expressing cells, preferably Icrac expressing cells containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and (b) determining the activity of the test compound on the calcium release-activated channel by assessing the reporter gene expression in said cells.

Abstract: The present invention relates to compositions and methods directed at screening or characterizing compounds that modulate the activity of calcium channels in cells preferably, calcium-release activated channels in cells. The compositions and methods can be used to produce inhibitors or activators of said channel, which represent leads or candidate therapeutic drugs for treating various pathological conditions. More specifically, the method comprises (a) contacting a test compound and a calcium channel activator, preferably an Icrac activator with a population of calcium channel expressing cells, preferably Icrac expressing cells containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and (b) determining the activity of the test compound on the calcium release-activated channel by assessing the reporter gene expression in said cells.

Abstract: The invention relates to the use of trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers for the preparation of a medicament to prevent and/or treat inflammatory somatic pain as well as chronic pain.

Abstract: The invention provides a combination of of trimebutine [2-dimethylamino-2-phenylbutyl-3, 4, 5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers with an opioid analgesic for the preparation of a medicament to prevent and/or treat pain or nociception.

Abstract: The invention relates to the use of trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers for the preparation of a medicament to prevent and/or treat inflammatory somatic pain as well as chronic pain.

Abstract: The present invention relates to compositions and methods directed at screening or characterizing compounds that modulate the activity of calcium channels in cells preferably, calcium-release activated channels in cells. The compositions and methods can be used to produce inhibitors or activators of said channel, which represent leads or candidate therapeutic drugs for treating various pathological conditions. More specifically, the method comprises (a) contacting a test compound and a calcium channel activator, preferably an Icrac activator with a population of calcium channel expressing cells, preferably Icrac expressing cells containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and (b) determining the activity of the test compound on the calcium release-activated channel by assessing the reporter gene expression in said cells.

Abstract: The invention relates to the use of trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers for the preparation of a medicament to prevent and/or treat arthritis, osteo-traumatic pain, and neuralgias.

Abstract: New cycloalkylalkylamines which are sigma-receptor ligands of formule (I) ##STR1## in which: R.sub.1 is H or lower alkyl; X and Y are H, OH, lower alkyl, lower alkoxy, halogen or nitrile; V.sub.1 and V.sub.2 together form a double bond attached to an oxygen atom or to a hydroxyimino radical, or are linked as an ethylenedioxy chain; A represents a valency bond, an oxygen atom, a methylene or an ethylene group; m is equal to 0, 1 or 2; n has the value of an integer from 1 to 5. Psychotropic drug which is also useful in gastroenterology.

Abstract: Xanthine compounds of the formula: ##STR1## in which: R.sub.1 is hydrogen or (C.sub.1 -C.sub.5) alkyl;R.sub.2 is hydrogen, (C.sub.1 -C.sub.5) alkyl optionally having a double bond, or benzyl;R.sub.3 is hydrogen or methyl;A is (CH.sub.2).sub.n, in which n is an integer from 1 to 4, optionally substituted, when n is higher than 1, by hydroxy;X is nitrogen or ##STR2## and the substituents R are each (C.sub.1 -C.sub.5) alkyl or they form together a polymethylene chain from C.sub.4 to C.sub.6, optionally containing an oxygen or a sulfur atom.These compounds and physiologically tolerable acid addition salts thereof may be used as medicines especially in the treatment of migraine and asthenia.

Abstract: Disubstituted polymethylene imines of the formula: ##STR1## in which: A is a straight or branched chain (C.sub.3 -C.sub.5) hydrocarbon containing radical optionally containing one or two double bond and optionally substituted by one or more hydroxy;n is zero, one or two;Z is oxygen or NH; andR is:either COR', in which R' is:(a) a straight or branched chain (C.sub.1 -C.sub.6), hydrocarbon containing radical, optionally containing one oxygen or sulfen or a double bond and optionally substituted by phenyl or substituted phenyl; or(b) phenyl, halophenyl, lower alkoxyphenyl, (di-or-tri-methylene) dioxyphenyl or;(c) furyl, thienyl, benzofuryl, benzothienyl or benzodioxannyl; or(d) ##STR2## in which R.sub.1 and R.sub.2 are hydrogen or lower alkyl or ##STR3## is a five or six membered heterocyclic radical which may contain an oxygen;or--SO.sub.2 R" in which R" is (C.sub.1 -C.sub.3) alkyl or phenyl.